Gilead Sciences (NASDAQ:GILD) Full Year 2024 Results

Key Financial Results

• Revenue: US$28.8b (up 6.0% from FY 2023).
• Net income: US$480.0m (down 92% from FY 2023).
• Profit margin: 1.7% (down from 21% in FY 2023).
• EPS: US$0.39 (down from US$4.54 in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Gilead Sciences Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) also surpassed analyst estimates significantly.

The primary driver behind last 12 months revenue was the United States segment contributing a total revenue of US$20.5b (71% of total revenue). The most substantial expense, totaling US$10.4b were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how GILD's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 8.3% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 5 warning signs for Gilead Sciences you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.